Revenue and EPS Exceed Expectations
Q3 2025 revenue reached $681 million, a 6% sequential increase, with non-GAAP EPS at $0.62, both at the high end of prior guidance.
Strong Performance in Medical and A&D Sectors
The medical sector saw a 15% sequential and 18% year-over-year growth. A&D revenue increased by 2% quarter-over-quarter and 26% year-over-year.
Record Free Cash Flow
Generated $25 million in free cash flow during Q3, contributing to more than $74 million over the last 12 months.
Strong Bookings and Strategic Wins
Continued momentum with new bookings and strategic customer wins in both engineering and manufacturing, supporting future growth.